CRISPR Therapeutics AG reported an insider ownership change involving Simeon George on June 5, 2026, in a Form 4 filed June 9. The filing indicates a change in George’s beneficial ownership of derivative securities, specifically stock options, rather than a reported open-market purchase or sale of ordinary shares. The disclosed option award is subject to continued service with CRISPR Therapeutics or one of its subsidiaries. According to the filing’s explanatory note, the options vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month after the grant date. The first installment vests on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting. The filing text provided does not show the full transaction table, so the number of options granted, the exercise price, transaction code, expiration date, and George’s exact derivative-security ownership after the transaction are not visible in the excerpt. No non-derivative share sale or purchase is described in the provided text. The action appears to be a routine equity-compensation grant, likely tied to board or service-based compensation, with vesting designed to align the insider’s incentives with continued service through the next annual meeting cycle. The form was signed on June 9, 2026, by Sasha Keough as attorney-in-fact for Simeon George.